15-18-1　ⓔ文献

  1. 日本泌尿器科学会・日本Men’s Health医学会「LOH症候群診療ガイドライン」検討ワーキング委員会：加齢男性性腺機能低下症候群 (LOH症候群) 診療の手引き，じほう，2007.

  2. Heinemann LA, Zimmermann T, et al: A new’Aging Males’Symptoms (AMS) rating scale. Aging Male, 1999; 2: 105–114.

  3. Tenover JS: Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab, 1992; 75: 1092–1098.

  4. Meier C, Nguyen TV, et al: Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med, 2008; 168: 47–54.

  5. Amory JK, Watts NB, et al: Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab, 2004; 89: 503–510.

  6. Svartberg J, Agledahl I, et al: Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res, 2008; 20: 378–387.

  7. Behre HH, Kliesch S, et al: Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab, 1997; 82: 2386–2390.

  8. Kenny AM, Prestwood KM, et al: Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci, 2000; 55: M492–M497.

  9. Fink HA, Ewing SK, et al: Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab, 2006; 91: 3908–3915.

  10. lsidori AM, Giannetta E, et al: Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle age men: a meta–analysis. Clin Endocrinol, 2005; 63: 280–293.

  11. Bassil N, Alkaade S, et al: The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag, 2009; 5: 427–448.

  12. Basurto L, Zarate A, et al: Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male, 2008; 11: 140–145.